All therapeutic evidence for SLU-PP-332 is still preclinical. Animal studies are scientifically interesting, but we did not identify established human treatment studies, so we do not yet know whether it works or is safe in people.
Still uncertain: Human benefit, dose, how the body handles it, interactions, exercise effects, weight loss and long-term safety.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
No therapeutic human administration evidence identified. A 2026 human-liver S9 study addresses metabolism/detection, not clinical exposure.
Regulatory status
No FDA/EMA-approved medicine identified.
Main limitations
Human exercise enhancement, weight loss, dose, pharmacokinetics, interactions or long-term safety.
Safety
Human PK, toxicity, carcinogenicity/reproductive safety and therapeutic window are unknown.
Evidence reviewed
2026-09-18
i
No therapeutic human administration evidence identified. A 2026 human-liver S9 study addresses metabolism/detection, not clinical exposure.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Human PK, toxicity, carcinogenicity/reproductive safety and therapeutic window are unknown.
Human pharmacokinetics, therapeutic window, organ toxicity, cardiovascular risk and long-term safety are unknown.
Technical details
Mechanism / biologyPan-ERR agonist that activates transcriptional programmes associated with oxidative metabolism/exercise adaptation in experimental models.
Route / formulation boundaryThis is a small molecule, not a peptide. Oral commercial capsules are not validated by preclinical papers.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceStudy-regimen evidence reviewed. No human dosing regimen identified; current literature remains preclinical, medicinal-chemistry and analytical.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
2outcome records
8linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
